反复低温冷冻不会影响 EpiPen® 和 Jext® 肾上腺素自动注射器的喷射量。

IF 1.3 4区 医学 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Felix N R Wood, Rosemary Hartley, Rebecca Boys, Timothy Parham, Jonathon Lowe, Matthew Warner
{"title":"反复低温冷冻不会影响 EpiPen® 和 Jext® 肾上腺素自动注射器的喷射量。","authors":"Felix N R Wood, Rosemary Hartley, Rebecca Boys, Timothy Parham, Jonathon Lowe, Matthew Warner","doi":"10.1080/22423982.2024.2367273","DOIUrl":null,"url":null,"abstract":"<p><p>It has previously been shown that EpiPen® autoinjectors are likely to activate normally following up to five excursions to -25°C but data about the post-freezing performance of other brands of adrenaline autoinjectors has not previously been published. Additionally, conditions experienced by polar medics may be substantially colder than this and the performance of adrenaline autoinjectors following more extreme freeze-thaw cycles remains uncharacterised. Investigators in Antarctica and the United Kingdom performed laboratory testing on two brands of adrenaline autoinjector, EpiPen® and Jext® (12 devices of each type). A single freeze-thaw cycle involved freezing the device to -80°C then allowing it to come to room temperature. Devices were exposed to 0, 1, 5 or 15 freeze-thaw cycles. The mass of liquid ejected from each device, when activated, was then measured. No significant differences in the mass of the liquid ejected was found between the test groups. Multiple freeze-thaw cycles to -80°C are unlikely to significantly impact the amount of adrenaline solution expelled from EpiPen® and EpiPen® autoinjectors. This preliminary finding encourages further work investigating the safety and effectiveness of adrenaline autoinjectors after exposure to very low temperatures. This information would be valuable for future polar medics planning and delivering medical provision in extreme environments.</p>","PeriodicalId":13930,"journal":{"name":"International Journal of Circumpolar Health","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182065/pdf/","citationCount":"0","resultStr":"{\"title\":\"Repeated freezing to very low temperatures does not impact the amount ejected from EpiPen® and Jext® adrenaline autoinjectors.\",\"authors\":\"Felix N R Wood, Rosemary Hartley, Rebecca Boys, Timothy Parham, Jonathon Lowe, Matthew Warner\",\"doi\":\"10.1080/22423982.2024.2367273\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>It has previously been shown that EpiPen® autoinjectors are likely to activate normally following up to five excursions to -25°C but data about the post-freezing performance of other brands of adrenaline autoinjectors has not previously been published. Additionally, conditions experienced by polar medics may be substantially colder than this and the performance of adrenaline autoinjectors following more extreme freeze-thaw cycles remains uncharacterised. Investigators in Antarctica and the United Kingdom performed laboratory testing on two brands of adrenaline autoinjector, EpiPen® and Jext® (12 devices of each type). A single freeze-thaw cycle involved freezing the device to -80°C then allowing it to come to room temperature. Devices were exposed to 0, 1, 5 or 15 freeze-thaw cycles. The mass of liquid ejected from each device, when activated, was then measured. No significant differences in the mass of the liquid ejected was found between the test groups. Multiple freeze-thaw cycles to -80°C are unlikely to significantly impact the amount of adrenaline solution expelled from EpiPen® and EpiPen® autoinjectors. This preliminary finding encourages further work investigating the safety and effectiveness of adrenaline autoinjectors after exposure to very low temperatures. This information would be valuable for future polar medics planning and delivering medical provision in extreme environments.</p>\",\"PeriodicalId\":13930,\"journal\":{\"name\":\"International Journal of Circumpolar Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182065/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Circumpolar Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/22423982.2024.2367273\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Circumpolar Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/22423982.2024.2367273","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

以前的研究表明,EpiPen® 自动注射器在摄氏零下 25 度的环境中最多可以正常启动五次,但有关其他品牌肾上腺素自动注射器冷冻后性能的数据以前尚未公布。此外,极地医疗人员所经历的条件可能比这还要冷得多,肾上腺素自动注射器在更极端的冻融循环后的性能仍未得到描述。南极洲和英国的研究人员对 EpiPen® 和 Jext® 两种品牌的肾上腺素自动注射器进行了实验室测试(每种设备各 12 支)。单次冻融循环包括将设备冷冻到零下 80 摄氏度,然后让其恢复到室温。装置分别经过 0、1、5 或 15 次冻融循环。然后测量每个装置在激活时喷出的液体质量。测试组之间喷出液体的质量没有明显差异。多次-80°C冻融循环不太可能对 EpiPen® 和 EpiPen® 自动注射器排出的肾上腺素溶液量产生重大影响。这一初步发现有助于进一步研究肾上腺素自动注射器暴露于极低温度后的安全性和有效性。这些信息对于未来极地医疗人员在极端环境中规划和提供医疗服务非常有价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Repeated freezing to very low temperatures does not impact the amount ejected from EpiPen® and Jext® adrenaline autoinjectors.

It has previously been shown that EpiPen® autoinjectors are likely to activate normally following up to five excursions to -25°C but data about the post-freezing performance of other brands of adrenaline autoinjectors has not previously been published. Additionally, conditions experienced by polar medics may be substantially colder than this and the performance of adrenaline autoinjectors following more extreme freeze-thaw cycles remains uncharacterised. Investigators in Antarctica and the United Kingdom performed laboratory testing on two brands of adrenaline autoinjector, EpiPen® and Jext® (12 devices of each type). A single freeze-thaw cycle involved freezing the device to -80°C then allowing it to come to room temperature. Devices were exposed to 0, 1, 5 or 15 freeze-thaw cycles. The mass of liquid ejected from each device, when activated, was then measured. No significant differences in the mass of the liquid ejected was found between the test groups. Multiple freeze-thaw cycles to -80°C are unlikely to significantly impact the amount of adrenaline solution expelled from EpiPen® and EpiPen® autoinjectors. This preliminary finding encourages further work investigating the safety and effectiveness of adrenaline autoinjectors after exposure to very low temperatures. This information would be valuable for future polar medics planning and delivering medical provision in extreme environments.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Circumpolar Health
International Journal of Circumpolar Health 医学-公共卫生、环境卫生与职业卫生
CiteScore
2.10
自引率
15.40%
发文量
51
审稿时长
6-12 weeks
期刊介绍: The International Journal of Circumpolar Health is published by Taylor & Francis on behalf of the Circumpolar Health Research Network [CircHNet]. The journal follows the tradition initiated by its predecessor, Arctic Medical Research. The journal specializes in circumpolar health. It provides a forum for many disciplines, including the biomedical sciences, social sciences, and humanities as they relate to human health in high latitude environments. The journal has a particular interest in the health of indigenous peoples. It is a vehicle for dissemination and exchange of knowledge among researchers, policy makers, practitioners, and those they serve. International Journal of Circumpolar Health welcomes Original Research Articles, Review Articles, Short Communications, Book Reviews, Dissertation Summaries, History and Biography, Clinical Case Reports, Public Health Practice, Conference and Workshop Reports, and Letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信